Chennai : Roche Pharma has announced the India launch of Phesgo – the ‘first ever’ fixed dose formulation in oncology to combine two monoclonal antibodies.
Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
‘Phesgo was first approved by the USFDA in June 2020 during the peak of the Covid pandemic, by the European Medicines Agency (EMA) in December 2020, and has been recognised in the NCCN treatment guidelines. In India, it was approved by the DCGI in October 2021 and the import license was granted in January 2022,’ it said.
